5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer

Clinical Trial ID NCT01216644

Rank	Title	Journal	Year	PubWeight™‹?›
1	Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.	Lancet Oncol	2016	1.53
2	Trial watch: Chemotherapy with immunogenic cell death inducers.	Oncoimmunology	2012	1.33
3	Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy.	Ann Oncol	2013	1.05
4	Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care.	J Hematol Oncol	2013	0.84
5	ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).	BMC Cancer	2016	0.84